Predictors of outcome of non-muscle-invasive and muscle-invasive bladder cancer

Ramy F. Youssef, Yair Lotan

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Bladder cancer is a major cause of morbidity and mortality. At initial diagnosis, 75% of patients present with non-muscle-invasive disease and 25% of patients have muscle-invasive or metastatic disease. Patients with noninvasive disease suffer from a high rate of recurrence and 10-30% will have disease progression. Patients with muscle-invasive disease are primarily treated with radical cystectomy, but frequently succumb to their disease despite improvements in surgical technique. In non-muscle-invasive disease, multiplicity, tumor size, and prior recurrence rates are the most important predictors for recurrence, while tumor grade, stage, and carcinoma in situ are the most important predictors for progression. The most common tool that clinicians use to predict outcomes after radical cystectomy is still the tumor-node-metastasis (TNM) staging system, with lymph node involvement representing the most important prognostic factor. However, the predictive accuracy of staging and grading systems are limited, and nomograms incorporating clinical and pathologic factors can improve prediction of bladder cancer outcomes. One limitation of current staging is the fact that tumors of a similar stage and grade can have significantly different biology. The integration of molecular markers, especially in a panel approach, has the potential to further improve the accuracy of predictive models and may also identify targets for therapeutic intervention or patients who will respond to systemic therapies.

Original languageEnglish (US)
Pages (from-to)369-381
Number of pages13
JournalTheScientificWorldJournal
Volume11
DOIs
StatePublished - Feb 14 2011

Fingerprint

Urinary Bladder Neoplasms
Muscle
cancer
muscle
Muscles
tumor
Tumors
Cystectomy
Recurrence
Neoplasms
Nomograms
Carcinoma in Situ
morbidity
Disease Progression
Lymph Nodes
Neoplasm Metastasis
Morbidity
Mortality
mortality
Therapeutics

Keywords

  • Bladder cancer
  • Bladder cancer markers
  • Outcome
  • Prognosis

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Environmental Science(all)
  • Medicine(all)

Cite this

Predictors of outcome of non-muscle-invasive and muscle-invasive bladder cancer. / Youssef, Ramy F.; Lotan, Yair.

In: TheScientificWorldJournal, Vol. 11, 14.02.2011, p. 369-381.

Research output: Contribution to journalArticle

@article{13efac00295e4485b8ca2fb53ba812e6,
title = "Predictors of outcome of non-muscle-invasive and muscle-invasive bladder cancer",
abstract = "Bladder cancer is a major cause of morbidity and mortality. At initial diagnosis, 75{\%} of patients present with non-muscle-invasive disease and 25{\%} of patients have muscle-invasive or metastatic disease. Patients with noninvasive disease suffer from a high rate of recurrence and 10-30{\%} will have disease progression. Patients with muscle-invasive disease are primarily treated with radical cystectomy, but frequently succumb to their disease despite improvements in surgical technique. In non-muscle-invasive disease, multiplicity, tumor size, and prior recurrence rates are the most important predictors for recurrence, while tumor grade, stage, and carcinoma in situ are the most important predictors for progression. The most common tool that clinicians use to predict outcomes after radical cystectomy is still the tumor-node-metastasis (TNM) staging system, with lymph node involvement representing the most important prognostic factor. However, the predictive accuracy of staging and grading systems are limited, and nomograms incorporating clinical and pathologic factors can improve prediction of bladder cancer outcomes. One limitation of current staging is the fact that tumors of a similar stage and grade can have significantly different biology. The integration of molecular markers, especially in a panel approach, has the potential to further improve the accuracy of predictive models and may also identify targets for therapeutic intervention or patients who will respond to systemic therapies.",
keywords = "Bladder cancer, Bladder cancer markers, Outcome, Prognosis",
author = "Youssef, {Ramy F.} and Yair Lotan",
year = "2011",
month = "2",
day = "14",
doi = "10.1100/tsw.2011.28",
language = "English (US)",
volume = "11",
pages = "369--381",
journal = "The Scientific World Journal",
issn = "2356-6140",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Predictors of outcome of non-muscle-invasive and muscle-invasive bladder cancer

AU - Youssef, Ramy F.

AU - Lotan, Yair

PY - 2011/2/14

Y1 - 2011/2/14

N2 - Bladder cancer is a major cause of morbidity and mortality. At initial diagnosis, 75% of patients present with non-muscle-invasive disease and 25% of patients have muscle-invasive or metastatic disease. Patients with noninvasive disease suffer from a high rate of recurrence and 10-30% will have disease progression. Patients with muscle-invasive disease are primarily treated with radical cystectomy, but frequently succumb to their disease despite improvements in surgical technique. In non-muscle-invasive disease, multiplicity, tumor size, and prior recurrence rates are the most important predictors for recurrence, while tumor grade, stage, and carcinoma in situ are the most important predictors for progression. The most common tool that clinicians use to predict outcomes after radical cystectomy is still the tumor-node-metastasis (TNM) staging system, with lymph node involvement representing the most important prognostic factor. However, the predictive accuracy of staging and grading systems are limited, and nomograms incorporating clinical and pathologic factors can improve prediction of bladder cancer outcomes. One limitation of current staging is the fact that tumors of a similar stage and grade can have significantly different biology. The integration of molecular markers, especially in a panel approach, has the potential to further improve the accuracy of predictive models and may also identify targets for therapeutic intervention or patients who will respond to systemic therapies.

AB - Bladder cancer is a major cause of morbidity and mortality. At initial diagnosis, 75% of patients present with non-muscle-invasive disease and 25% of patients have muscle-invasive or metastatic disease. Patients with noninvasive disease suffer from a high rate of recurrence and 10-30% will have disease progression. Patients with muscle-invasive disease are primarily treated with radical cystectomy, but frequently succumb to their disease despite improvements in surgical technique. In non-muscle-invasive disease, multiplicity, tumor size, and prior recurrence rates are the most important predictors for recurrence, while tumor grade, stage, and carcinoma in situ are the most important predictors for progression. The most common tool that clinicians use to predict outcomes after radical cystectomy is still the tumor-node-metastasis (TNM) staging system, with lymph node involvement representing the most important prognostic factor. However, the predictive accuracy of staging and grading systems are limited, and nomograms incorporating clinical and pathologic factors can improve prediction of bladder cancer outcomes. One limitation of current staging is the fact that tumors of a similar stage and grade can have significantly different biology. The integration of molecular markers, especially in a panel approach, has the potential to further improve the accuracy of predictive models and may also identify targets for therapeutic intervention or patients who will respond to systemic therapies.

KW - Bladder cancer

KW - Bladder cancer markers

KW - Outcome

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=79952422386&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952422386&partnerID=8YFLogxK

U2 - 10.1100/tsw.2011.28

DO - 10.1100/tsw.2011.28

M3 - Article

VL - 11

SP - 369

EP - 381

JO - The Scientific World Journal

JF - The Scientific World Journal

SN - 2356-6140

ER -